UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

Industry body says agreement doesn’t address ‘longstanding industry concerns’ about IP | Deal criticised for ‘lack of detail’ on IP, particularly for UK life sciences and general legal sector | £25.5bn deal offers provisions for medical devices | Smith+Nephew hopes deal will help build trade for healthcare.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Fed Circ refuses to stay Novartis feud with MSN over Entresto

Moderna entities must face infringement suits, UPC rules

Baker McKenzie adds London partner with ‘enviable’ expertise

‘Keep calm and carry on’: UK+ regime stays post-Brexit

As AI shakes up pharma and biotech, can patent law keep up?

UK court clears the way for Amgen and Samsung to launch biosimilars

SK Bioscience prevails over Pfizer in pneumococcal vaccine dispute

‘It’s going to be very different’: INTA CEO shares London meeting plans

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

Editor's picks

Editor's picks

More features